Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0429 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1600 mg twice a day | EXPERIMENTAL | MK0429 |
| 200 mg twice a day | EXPERIMENTAL | MK0429 |
| 800 mg twice a day | EXPERIMENTAL | MK0429 |
| 400 mg twice a day | EXPERIMENTAL | MK0429 |
| Name | Type | Description |
|---|---|---|
| MK0429 | DRUG | - |
| Comparator: MK0429 | DRUG | Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone. Disease. |
Inclusion Criteria: * Person is a women with osteoporosis who is unwilling or unable to take other treatments for osteoporosis Exclusion Criteria: * Person has had a previous fracture * Person has rheumatoid arthritis. Person has has certain types of cancer * Person has donated blood or has been ...
MK0429 is a small molecule being studied for use in prostatic neoplasms, specifically prostate cancer patients with metastatic bone disease, and in post-menopausal osteoporosis. It is an investigational drug and remains in clinical development.
MK0429 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company has sponsored clinical trials evaluating the drug in prostate cancer and post-menopausal osteoporosis.
MK0429 has completed a Phase 1 trial in prostate cancer and a Phase 2 trial in post-menopausal osteoporosis. The drug is investigational and has not been approved by regulatory authorities.
MK0429 has been studied in two completed trials. NCT00302471 was a Phase 1 study in prostate cancer patients with metastatic bone disease, enrolling 29 male participants. NCT00533650 was a Phase 2 proof-of-concept study in post-menopausal osteoporosis, enrolling 227 female participants.
MK0429 is also known by the name MK-0429. It is a small molecule being investigated by Merck for its effects on bone-related conditions, including metastatic bone disease in prostate cancer and post-menopausal osteoporosis.